E
Elisa de Stanchina
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 268
Citations - 26387
Elisa de Stanchina is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 65, co-authored 201 publications receiving 21076 citations. Previous affiliations of Elisa de Stanchina include Kettering University & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
PML Is a Direct p53 Target that Modulates p53 Effector Functions
Elisa de Stanchina,Emmanuelle Querido,Masako Narita,Ramana V. Davuluri,Pier Paolo Pandolfi,Gerardo Ferbeyre,Scott W. Lowe +6 more
TL;DR: It is shown that the promyelocytic leukemia gene (PML) is itself a p53 target gene that also acts downstream of p53 to potentiate its antiproliferative effects, and is required for PML induction in response to oncogenes and DNA damaging chemotherapeutics.
Journal ArticleDOI
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa Rodrik-Outmezguine,Masanori Okaniwa,Zhan Yao,Chris J. Novotny,Claire McWhirter,Arpitha Banaji,Helen Won,Wai Wong,M.F. Berger,Elisa de Stanchina,Derek Barratt,Sabina Cosulich,Teresa Klinowska,Neal Rosen,Kevan M. Shokat,Kevan M. Shokat +15 more
TL;DR: A new class of mTOR inhibitors is reported which overcomes resistance to existing first and second generation inhibitors and exploits the unique juxtaposition of two drug binding pockets to create a bivalent interaction that allows inhibition of these resistant mutants.
Journal ArticleDOI
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf,Nadine Jahchan,Peter J. Schnorr,Sandra Cristea,Aaron M. Ring,Roy Louis Maute,Anne Kathrin Volkmer,Jens Peter Volkmer,Jie Liu,Jing Shan Lim,Dian Yang,Garrett Seitz,Thuyen Nguyen,Di Wu,Kevin Jude,Heather Guerston,Amira A. Barkal,Francesca Trapani,Julie George,John T. Poirier,Eric E. Gardner,Linde A. Miles,Elisa de Stanchina,Shane Lofgren,Hannes Vogel,Monte M. Winslow,Caroline Dive,Roman K. Thomas,Charles M. Rudin,Matt van de Rijn,Ravindra Majeti,K. Christopher Garcia,Irving L. Weissman,Julien Sage +33 more
TL;DR: Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture, and this approach could enable personalized immunotherapeutic regimens in patients with S CLC and other cancers.
Journal ArticleDOI
Oncogenic ras and p53 cooperate to induce cellular senescence.
Gerardo Ferbeyre,Elisa de Stanchina,Athena W. Lin,Emmanuelle Querido,Mila E. McCurrach,Gregory J. Hannon,Scott W. Lowe +6 more
TL;DR: Results indicate that oncogenic activation of the MAP kinase pathway in murine fibroblasts converts p53 into a senescence inducer through both quantitative and qualitative mechanisms.
Journal ArticleDOI
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Eloisi Caldas-Lopes,Leandro Cerchietti,James H. Ahn,Cristina C. Clement,Ana I. Robles,Anna Rodina,Kamalika Moulick,Tony Taldone,Alexander Gozman,Yunke Guo,Nian Wu,Elisa de Stanchina,Julie D. White,Steven S. Gross,Yuliang Ma,Lyuba Varticovski,Ari Melnick,Gabriela Chiosis +17 more
TL;DR: The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp 90 inhibitor PU-H71 for clinical trials involving patients with TNBC.